RDHL Stock Analysis: Buy, Sell, or Hold?
RDHL - Redhill Biopharma Ltd.
$0.74
0.05 (6.64%)
▲
5d:
+0.43%
30d:
-19.76%
90d:
-9.1%
BUY
MODERATE Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Apr 09, 2026
0d
Get Alerted When RDHL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RDHL shows positive signals but monitor for confirmation. Moderate conviction.
💡 BUY OPPORTUNITY: RDHL shows positive signals but monitor for confirmation. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: RDHL is currently trading at $0.74, which is considered oversold relative to its 30-day fair value range of $0.74 to $0.90.
Technical Outlook: Technically, RDHL is in a downtrend. The price is currently testing key support at $0.80. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 6.6% recently.
Market Sentiment: RDHL has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $19000.00 (+2570941.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RDHL is in a downtrend. The price is currently testing key support at $0.80. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 6.6% recently.
Market Sentiment: RDHL has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $19000.00 (+2570941.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.74 -
$0.90
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.6%)
- BULLISH: Trading 2570941.9% below Wall St target ($19000.00)
Trading Range Analysis
30-Day Trading Range
$0.74 -
$0.90
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.80
Resistance Level
$1.09
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1428.57
Wall Street Target
$19000.00
(+2570941.9%)
Revenue Growth (YoY)
58.6%
Profit Margin
-150.0%
Share & Embed Analysis
Last updated: July 15, 2026 6:34 AM ET
Data refreshes hourly during market hours. Next update: 7:34 AM
Data refreshes hourly during market hours. Next update: 7:34 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RDHL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Gilead Raday
SELL
15740000 shares
2026-04-06
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 58 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 54 HOLD |
